ArticleCureus2025
Reversible Cardiomyopathy in Polyarteritis Nodosa: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyarteritis nodosa (PAN) is a rare vasculitis that affects the medium-sized arteries, often involving numerous organ systems, including the heart. In this report, we present a case of a 26-year-old male with a two-month history of systemic symptoms, abdominal pain, and intrinsic acute kidney injury, who ultimately developed acute hypoxic respiratory failure secondary to acute pulmonary edema. His echocardiogram was notable for biventricular systolic dysfunction with reduced ejection fraction and regional wall motion abnormalities, but no coronary angiogram was pursued. His cardiac magnetic resonance imaging (MRI) study did not demonstrate evidence of myocarditis per Lake Louise criteria. Renal biopsy was consistent with medium-vessel vasculitis, confirming the diagnosis of PAN. He was initiated on immunosuppression with methylprednisolone and cyclophosphamide, and subsequently placed on guideline-directed medical therapy (GDMT) with metoprolol, sacubitril-valsartan, and dapagliflozin. At one-year follow-up, his symptoms had resolved, and his ejection fraction had normalized. Our case uniquely describes a cardiomyopathy phenotype that was likely stress-mediated in the context of active inflammation and was reversible with immunosuppression and GDMT, without the need for revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.